MAP2K7 and neurofibromatosis type 1: Recent clinical trials have shown promising results with MEK inhibitors, such as selumetinib and mirdametinib, in NF1-related neurofibromas, demonstrating significant tumor shrinkage, pain relief, and improved quality of life with tolerable safety profiles (12, 13).